Post-aggressive immunosuppression
Conditions
Brief summary
Number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day
Detailed description
Evolution and kinetics of mHLA-DR measured at D0, D1, D2, D3, D7 and D28 or at discharge from intensive care if earlier (D0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo, Evolution and kinetics of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at D0, D3 and D7, or at discharge from intensive care if it occurs before (D0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo., Mortality rate at D28 and D90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo, The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo, Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo, Number of antibiotic-free days at 28 days after randomization, Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo, Evolution and kinetics of lymphocyte count measured on D0, D1, D2, D3, D7 and D28 or upon discharge from intensive care if this occurs earlier (D0 corresponding to the day of inclusion in the study) between patients who received recombinant interferon gamma-1b compared with placebo., Changes in the transcriptome profile of circulating PBMC using scRNAseq analysis measured at D0, D3 and D7 or at discharge from intensive care if earlier.
Interventions
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day | — |
Secondary
| Measure | Time frame |
|---|---|
| Evolution and kinetics of mHLA-DR measured at D0, D1, D2, D3, D7 and D28 or at discharge from intensive care if earlier (D0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo, Evolution and kinetics of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at D0, D3 and D7, or at discharge from intensive care if it occurs before (D0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo., Mortality rate at D28 and D90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo, The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo, Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo, Num | — |
Countries
France